ASK THE DATA

EXERCISE-one

General

Run 31 Aug · 16:10

Run 31 Aug · 16:09

Run 26 Aug · 18:29

Run 26 Aug · 18:28

Run 26 Aug · 18:27

Run 24 Aug · 19:21

Run 24 Aug · 10:44

exercise-2

General Run 31 Aug · 12:13 Run 31 Aug · 12:04 Run 31 Aug · 12:04 Run 31 Aug · 11:56 Run 31 Aug · 11:53 Run 31 Aug · 11:13 Run 31 Aug · 10:59 Run 31 Aug · 10:52 Run 31 Aug · 10:47 Run 31 Aug · 10:44 Run 31 Aug · 10:36 Run 31 Aug · 10:17

EXERCISE one

Documents

0_Candidate_Brief.pdfreference - not analysed94 KB

1_Company_Briefing.pdfcompany briefing68 KB

2_Market_Landscape.pdfmarket landscape87 KB

3a_Facilities_Portugal.csvPortugal · facility register39 KB

3b_Facilities_Germany.xlsxGermany · facility register30 KB

3c_Facilities_Netherlands.htmlNetherlands · facility register58 KB

3d_Facilities_Poland.csvPoland · facility register38 KB

3e_Master_Registry.csvmaster registry54 KB

4_Funding_Call.pdffunding call41 KB

5a_Screening_Report_Portugal.pdfPortugal · screening report3 KB

5b_Screening_Report_Germany.pdfGermany · screening report3 KB

5c_Screening_Report_Netherlands.htmlNetherlands · screening report1 KB

5d_Screening_Report_Poland.xlsxPoland · screening report5 KB

6_Competitor_Brief_OncoStream.pdfcompetitor brief3 KB

Runs

31 Aug · 16:10recommends NetherlandsGlide

1 check failed ▾

CHK-02 · Competitor volume vs addressable market FAIL handled

OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.

handled: the company-reported figure is excluded from the model; the independent share estimate is used

A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.

CHK-03 · Competitor claim vs its own analyst share estimate WARN handled

fails for Germany

handled: same figure as CHK-02, excluded from the model

The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.

Report

31 Aug · 16:09recommends NetherlandsCruise → Glide

1 check failed ▾

CHK-02 · Competitor volume vs addressable market FAIL handled

handled: the company-reported figure is excluded from the model; the independent share estimate is used

A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.

CHK-03 · Competitor claim vs its own analyst share estimate WARN handled

fails for Germany

handled: same figure as CHK-02, excluded from the model

The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.

Report

26 Aug · 18:29recommends NetherlandsScout β74 from cache

1 check failed ▾

CHK-02 · Competitor volume vs addressable market FAIL handled

handled: the company-reported figure is excluded from the model; the independent share estimate is used

A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.

CHK-03 · Competitor claim vs its own analyst share estimate WARN handled

fails for Germany

handled: same figure as CHK-02, excluded from the model

The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.

Report

26 Aug · 18:28recommends NetherlandsOverdrivegpt-5-mini · 40 from cache

1 check failed ▾

CHK-02 · Competitor volume vs addressable market FAIL handled

handled: the company-reported figure is excluded from the model; the independent share estimate is used

A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.

CHK-03 · Competitor claim vs its own analyst share estimate WARN handled

fails for Germany

handled: same figure as CHK-02, excluded from the model

The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.

Report

26 Aug · 18:27recommends NetherlandsAfterburnergpt-5-mini · 7 from cache

1 check failed ▾

CHK-02 · Competitor volume vs addressable market FAIL handled

handled: the company-reported figure is excluded from the model; the independent share estimate is used

A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.

CHK-03 · Competitor claim vs its own analyst share estimate WARN handled

fails for Germany

handled: same figure as CHK-02, excluded from the model

The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.

Report

26 Aug · 18:27recommends NetherlandsCruise → Glide

1 check failed ▾

CHK-02 · Competitor volume vs addressable market FAIL handled

handled: the company-reported figure is excluded from the model; the independent share estimate is used

A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.

CHK-03 · Competitor claim vs its own analyst share estimate WARN handled

fails for Germany

handled: same figure as CHK-02, excluded from the model

The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.

Report

24 Aug · 19:21recommends NetherlandsGlide

1 check failed ▾

CHK-02 · Competitor volume vs addressable market FAIL

A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.

CHK-03 · Competitor claim vs its own analyst share estimate WARN

fails for Germany

The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.

Report

24 Aug · 10:44recommends NetherlandsAI off

1 check failed ▾

CHK-02 · Competitor volume vs addressable market FAIL

A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.

CHK-03 · Competitor claim vs its own analyst share estimate WARN

fails for Germany

The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.

Report

New exercise

EXERCISE one

Documents

New run

Runs